Novavax COVID-19 vaccine found to be 96.4% effective in final analysis of UK Phase-3 study

Novavax COVID-19 vaccine found to be 96.4% effective in final analysis of UK Phase-3 study The vaccine would be manufactured at eight locations including the Serum Institute of India, with which Novavax has an agreement to produce around 2 billion doses a year.

No comments:

Post a Comment